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Abstract
Whether the subtype of atrial fibrillation affects outcomes after transcatheter aortic valve
replacement for aortic stenosis is unclear. The nationwide FinnValve registry included 2130
patients who underwent primary after transcatheter aortic valve replacement for aortic ste-
nosis during 2008–2017. Altogether, 281 (13.2%) patients had pre-existing paroxysmal
atrial fibrillation, 651 (30.6%) had pre-existing non-paroxysmal atrial fibrillation and 160
(7.5%) were diagnosed with new-onset atrial fibrillation during the index hospitalization. The
median follow-up was 2.4 (interquartile range: 1.6–3.8) years. Paroxysmal atrial fibrillation
did not affect 30-day or overall mortality (p-values >0.05). Non-paroxysmal atrial fibrillation
demonstrated an increased risk of overall mortality (hazard ratio: 1.61, 95% confidence
interval: 1.35–1.92; p<0.001), but not 30-day mortality (p = 0.084). New-onset atrial fibrilla-
tion demonstrated significantly increased 30-day mortality (hazard ratio: 2.76, 95% confi-
dence interval: 1.25–6.09; p = 0.010) and overall mortality (hazard ratio: 1.68, 95%
confidence interval: 1.29–2.19; p<0.001). The incidence of early or late stroke did not differ
between atrial fibrillation subtypes (p-values >0.05). In conclusion, non-paroxysmal atrial
fibrillation and new-onset atrial fibrillation are associated with increased mortality after trans-
catheter aortic valve replacement for aortic stenosis, whereas paroxysmal atrial fibrillation
has no effect on mortality. These findings suggest that non-paroxysmal atrial fibrillation
rather than paroxysmal atrial fibrillation may be associated with structural cardiac damage
which is of prognostic significance in patients with aortic stenosis undergoing transcatheter
aortic valve replacement.
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Introduction
Transcatheter aortic valve replacement (TAVR) has demonstrated its efficacy in the treatment
of severe symptomatic aortic stenosis (AS) among patients who are inoperable or at a high or
moderate surgical risk [1, 2]. Atrial fibrillation (AF) and AS share multiple important risk fac-
tors, and AS causes a chronic increase in left ventricular filling pressure, which further predis-
poses to AF. Indeed, AF is an exceedingly common condition in the presence of AS with a 16–
51% prevalence among patients scheduled for TAVR [3]. Furthermore, new-onset AF is a
common finding during the immediate postoperative period after TAVR with the incidence
ranging from 6 to 35% [4–6]. AF carries important prognostic implications in patients with
AS, and the adverse effect of pre-existing AF on mortality in patients undergoing TAVR is
well-established [3, 5–10]. However, little is known about whether mortality outcomes differ
between patients with paroxysmal or permanent AF and there is conflicting evidence on the
prognostic effect of new-onset AF after TAVR [7–9]. Moreover, stroke is an important adverse
event after TAVR affecting up to 5% of patients scheduled for the procedure, while the effect
of AF on stroke incidence in this population is currently unclear [7, 11]. The aim of the current
study was to assess the effect of the subtype of pre-existing AF on outcomes after TAVR for AS
and to explore the influence of new-onset AF on mortality in the multicenter FinnValve
registry.
Material and methods
Study population
The FinnValve registry is a Finnish multicenter nationwide registry including retrospectively
collected data from consecutive patients undergoing TAVR or surgical aortic valve replace-
ment with a bioprosthesis for severe AS at all five Finnish university hospitals (Turku, Hel-
sinki, Kuopio, Tampere and Oulu) between January 2008 and November 2017 (Clinical trial
registration: ClinicalTrials.gov Identifier: NCT03385915) [12]. The study protocol was
approved by the Institutional Review Boards of all participating centers and the Ethics Com-
mittee of the National Institute for Health and Welfare. Informed consent was waived due to
the retrospective registry nature of the study. The study conforms to the Declaration of Hel-
sinki as revised in 2002.
All patients over the age of 18 years with AS undergoing TAVR or surgical aortic valve
replacement with a bioprosthesis during the study period meeting the inclusion criteria were
included in the registry [12]. The exclusion criteria of the registry were previous TAVR or sur-
gical aortic valve intervention, concomitant major cardiac procedure involving the ascending
aorta or other heart valves or structures, surgical or transcatheter procedure for isolated aortic
valve regurgitation and acute endocarditis. Finally, 2130 patients undergoing TAVR and 4333
patients undergoing surgical aortic valve replacement were included in the registry. The cur-
rent analysis focused only on patients on whom TAVR was performed.
The diagnosis and subtype of atrial fibrillation was determined from the clinical records of
the study patients undergoing TAVR. Patients were classified in to four categories according
to presence and subtype of AF: pre-existing paroxysmal AF, pre-existing non-paroxysmal AF,
new-onset AF and no AF. Non-paroxysmal AF included chronic and persistent AF. New-
onset AF was defined as AF diagnosed during the index hospitalization at the operative center.
Among the patients undergoing TAVR, 281 (13.2%) patients had pre-existing paroxysmal AF,
651 (30.6%) patients had pre-existing non-paroxysmal AF and 160 (7.2%) patients were diag-
nosed with new-onset AF, while 1038 (48.7%) patients had no history of AF at the time of hos-
pital discharge.
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Study protocol
Data on baseline and operative characteristics and postoperative outcomes were retrospec-
tively collected in a standardized online electronic data collection form. Data on the date of
death were obtained from the Population Register Center, a governmental agency, which
reviews all death certificates issued in Finland. Data on cardiovascular interventions were
obtained from the Finnish National Institute for Health and Welfare registry, which collects
information on the diagnosis and treatment of patients admitted to any local, regional or ter-
tiary hospital. The last day of follow-up was January 26th, 2019. Follow-up was considered
complete for all patients except for those not residing in Finland, and their follow-up was trun-
cated at hospital discharge.
Definition criteria
Baseline variables were defined according to the EuroSCORE II criteria [13]. Coronary artery
disease was defined as stenosis of�50% of any of the main coronary arteries. Severe frailty was
defined as Geriatric Status Scale (GSS) 2–3 [14]. Pulmonary disease was defined as long-term
use of bronchodilators or steroids for lung disease. Extracardiac arteriopathy was defined as
one or more of the following: claudication, carotid occlusion or>50% stenosis, amputation
for arterial disease and previous or planned intervention on the abdominal aorta, limb arteries
or carotid arteries. Poor mobility was defined as severe impairment of mobility due to muscu-
loskeletal or neurological dysfunction. The patients were defined as having a critical preopera-
tive state if one or more of the following were present preoperatively: ventricular tachycardia
or ventricular fibrillation or aborted sudden death, preoperative cardiac massage, preoperative
ventilation before anesthetic room, preoperative inotropes or intra-aortic balloon pump and
preoperative acute renal failure. Anemia was defined according to the World Health Organiza-
tion criteria as hemoglobin <12 g/dL in women and<13 g/dL in men. Life-threatening or
major bleeding was defined according to the Valve Academic Research Consortium 2 criteria
[15]. All TAVR devices were classified as older or newer generation prostheses. CoreValve
(Medtronic, Minneapolis, MN, USA), Engager (Medtronic, Minneapolis, MN, USA), Portico
(St. Jude Medical, Minneapolis, MN, USA) Sapien (Edwards Lifesciences, Irvine, CA, USA)
and Sapien XT (Edwards Lifesciences, Irvine, CA, USA) were considered older generation
prostheses. Lotus (Boston Scientific, Marlborough, MA, USA), Lotus Edge (Boston Scientific,
Marlborough, MA, USA), Evolut (Medtronic, Minneapolis, MN, USA), Evolut R (Medtronic,
Minneapolis, MN, USA), Evolut Pro (Medtronic, Minneapolis, MN, USA), Sapien 3 (Edwards
Lifesciences, Irvine, CA, USA) and Acurate Neo (Boston Scientific, Marlborough, MA, USA)
were considered newer generation prostheses.
Outcome measures
The primary outcome measure of the current study was all-cause overall mortality. The sec-
ondary outcome measures were all-cause 30-day mortality and 5-year mortality, early stroke
occurring during the index hospitalization, late stroke occurring after discharge as well as
combined early or late stroke. Outcome analyses were not landmarked.
Statistical analysis
Statistical analyses were performed with the IBM SPSS Statistics software (version 26.0, SPSS,
Inc., Chicago, Illinois) and R software (version 4.0.2, https://www.R-project.org). The normal-
ity assumption of continuous variables was assessed visually and with the Kolmogorov-Smir-
nov test of normality. Continuous data are presented as median (interquartile range) and
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categorical variables as absolute number and percentage. The Fisher’s exact test and the chi-
square test were used to compare differences between proportions, and the Kruskal-Wallis test
and the Mann-Whitney U-test to analyze continuous variables. The Kaplan-Meier method
was used to assess survival. Differences in survival between patients with paroxysmal, non-par-
oxysmal or new-onset AF and those without AF were evaluated with the log-rank test. A step-
wise Cox proportional-hazards model with the Wald backward method was used to determine
the adjusted hazard of overall, 30-day and 5-year mortality mortality associated with AF. All
variables with p<0.1 in univariate Cox regression analyses were included in to the multiple
Cox model. The proportional hazards assumption was ensured by assessing the test based on
Schoenfeld residuals, as well as by graphical assessment of the ln-ln plot of the survival curves.
Binary logistic regression models with the Wald backward method were used to define the
adjusted odds ratio of early, late or any stroke during the follow-up. A binary logistic regres-
sion analysis with the Wald backward method was also performed to assess the independent
predictors of new-onset AF. The goodness of fit of the binary logistic regression models were
estimated by the Hosmer-Lemeshow’s test. All variables with p<0.1 in univariate analyses
were included in to the logistic regression models. Two-sided differences were considered sig-
nificant if the null hypothesis could be rejected at the 0.05 probability level.
Results
The median age of the patients was 82.4 (78.0–85.8) years and 958 (45.0%) were men. The
baseline and operative characteristics of the patients are presented in Table 1.
During the follow-up (median 2.4 (1.6–3.89 years), the primary outcome measure of all-
cause mortality occurred in 85 (30.2%) patients with paroxysmal AF, 265 (40.7%) patients with
non-paroxysmal AF and 71 (44.4%) patients with new-onset AF. The median survival time
was 4.6 (2.2–7.0) years in patients with non-paroxysmal AF, 5.2 (2.7–9.0) years in patients with
paroxysmal AF, 4.5 (3.2–5.1) years in patients with new-onset AF and 6.6 (3.6–8.6) years in
those with no AF (log-rank <0.001). The hazard ratio (HR) of all-cause mortality was 1.36
(95% confidence interval (CI): 1.06–1.74; p = 0.014) for paroxysmal AF, 1.81 (95% CI: 1.52–
2.15; p<0.001) for non-paroxysmal AF and 1.84 (95% CI: 1.1.42–2.39; p<0.001) for new-onset
AF as compared with the 259 (25.0%) patients without AF. Survival in patients with paroxys-
mal, non-paroxysmal, new-onset and no AF before TAVR are presented in Fig 1.
The adjusted risk estimates of study outcomes are shown in Table 2. After adjusting for
baseline and operative covariates, non-paroxysmal and new-onset AF were associated with
increased all-cause mortality compared to no AF, whereas paroxysmal AF was not. Compared
to pre-existing non-paroxysmal AF, lesser hazards of overall mortality were observed in
patients with no AF (HR: 0.62, 95% CI: 0.52–0.74, p<0.001) and pre-existing paroxysmal AF
(HR: 0.76, 95% CI: 0.59–0.97, p = 0.029), whereas similar hazard was observed in patients with
new-onset AF (HR: 0.89, 95% CI: 0.68–1.16, p = 0.387). Higher odds of 30-day mortality was
observed in those with new-onset AF, while those with paroxysmal or non-paroxysmal AF
demonstrated no difference in contrast to patients with no AF (Table 2). No difference in the
adjusted odds of early or late stroke between those with no AF, paroxysmal AF, non-paroxys-
mal AF or new-onset AF was observed (Table 2).
Among the patients with no previous history of AF before the TAVR procedure, the inde-
pendent predictors of new-onset AF were critical preoperative state (odds ratio (OR: 2.77; 95%
CI: 1.20–6.43; p = 0.017), transapical access (OR: 2.63; 95% CI: 1.13–6.10; p = 0.025) and older
than third generation prosthesis (OR: 1.57; 95% CI: 1.06–2.32; p = 0.025). Compared to
patients who received a third generation TAVR prosthesis, moderate to severe paravalvular
regurgitation was more common (1.9% vs. 7.2%, p<0.001) and operative risk higher as
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Table 1. Baseline and operative characteristics.
Covariates No AF n = 1038 Paroxysmal AF n = 281 Non-paroxysmal AF n = 651 New-onset AF n = 160 P value
Age, years 82.1 (77.9–85.7) 82.5 (77.1–85.7) 82.6 (78.8–86.2) 82.6 (78.2–85.6) 0.131
Male sex 453 (43.6) 115 (40.9) 318 (48.8) 72 (45.0) 0.088
Diabetes 266 (25.6) 79 (28.1) 226 (34.7) 34 (21.3) <0.001
Coronary artery disease 292 (28.1) 75 (26.7) 181 (27.8) 55 (34.4) 0.339
History of myocardial infarction 134 (12.9) 52 (18.5) 94 (14.4) 25 (15.6) 0.115
Recent myocardial infarction 27 (2.6) 10 (3.6) 9 (1.4) 3 (1.9) 0.174
Extracardiac arteriopathy 205 (19.7) 46 (16.4) 126 (19.4) 35 (21.9) 0.501
History of stroke or TIA 167 (16.1) 61 (21.7) 128 (19.7) 28 (17.5) 0.093
Pulmonary disease 209 (20.1) 71 (25.3) 138 (21.2) 38 (23.8) 0.259
Permanent pacemaker 62 (6.0) 41 (14.6) 109 (16.7) 4 (2.5) <0.001
Active malignancy 39 (3.8) 11 (3.9) 26 (4.0) 8 (5.0) 0.903
Acute heart failure within 90 days 105 (10.1) 52 (18.5) 125 (19.2) 26 (16.3) <0.001
Previous cardiac surgery 201 (19.4) 42 (14.9) 160 (24.6) 28 (17.5) 0.003
Poor mobility 82 (7.9) 23 (8.2) 82 (12.6) 19 (11.9) 0.008
Severe frailty 136 (13.1) 40 (14.2) 114 (17.5) 28 (17.5) 0.069
eGFR, mL/min/1.73 m2 66.4 (52.9–82.0) 60.5 (45.4–75.8) 58.7 (43.8–76.3) 67.3 (54.5–84.8) <0.001
eGFR <30 mL/min/1.73 m2) 32 (3.1) 15 (5.3) 29 (4.5) 7 (4.4) 0.258
BMI, kg/m2 26.6 (23.8–30.1) 26.9 (24.0–29.7) 26.4 (23.9–30.1) 26.0 (23.7–29.3) 0.693
Anemia 463 (44.6) 151 (53.7) 300 (46.1) 81 (50.6) 0.038
CHA2DS2-VASc score 4 (3–5) 4 (3–5) 4 (4–5) 5 (4–5) <0.001
Preoperative antithrombotic therapy <0.001
None 177 (17.1) 12 (4.3) 12 (1.8) 23 (14.4)
AC 56 (5.4) 161 (57.3) 520 (79.9) 16 (10.0)
AC and SAPT 43 (4.1) 52 (18.5) 76 (11.7) 8 (5.0)
AC and DAPT 9 (0.9) 14 (5.0) 22 (3.4) 4 (2.5)
SAPT 621 (59.8) 30 (10.7) 17 (2.6) 89(55.6)
DAPT 132 (12.7) 12 (4.3) 4 (0.6) 20 (12.5)
Dyspnea, NYHA <0.001
Class I 14 (1.3) 3 (1.1) 0 (0.0) 0 (0.0)
Class II 212 (20.4) 42 (14.9) 68 (10.4) 24 (15.0)
Class III 700 (67.4) 199 (70.8) 501 (77.0) 123 (76.9)
Class IV 112 (10.8) 37 (13.2) 82 (12.6) 13 (8.1)
Combined aortic valve stenosis and regurgitation 344 (32.2) 106 (37.7) 183 (28.1) 43 (26.9) 0.016
Aortic valve maximum gradient, mmHg 78 (65–94) 75 (63–85) 72 (59–85) 76 (65–93) <0.001
Aortic valve mean gradient, mmHg 48 (40–59) 45 (38–54) 43 (35–53) 47 (39–60) <0.001
Recent aortic valve balloon valvuloplasty 17 (1.6) 15 (5.3) 25 (3.8) 8 (5.0) 0.001
Left ventricle ejection fraction <0.001
>50% 788 (76.1) 207 (73.7) 421 (64.8) 114 (71.3)
31–50% 213 (20.6) 66 (23.5) 192 (29.5) 35 (21.9)
21–30% 24 (2.3) 8 (2.8) 29 (4.5) 11 (6.9)
<21% 10 (1.0) 0 (0.0) 8 (1.2) 0 (0.0)
Systolic pulmonary artery pressure� <0.001
<31 mmHg 396 (46.4) 84 (35.9) 132 (22.8) 52 (37.7)
31–55 mmHg 359 (42.1) 113 (48.3) 320 (55.4) 61 (44.2)
>55 mmHg 98 (11.5) 37 (15.8) 126 (21.8) 25 (18.1)
STS score, % 3.4 (2.5–5.0) 4.2 (2.9–6.1) 4.1 (2.9–5.7) 3.8 (2.6–5.5) <0.001
EuroSCORE II, % 4.5 (2.6–7.8) 4.5 (2.8–8.3) 6.0 (3.6–10.3) 5.1 (3.0–8.7) <0.001
(Continued)
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assessed by the STS score (3.23 (2.35–4.57) vs. 4.20 (2.99–6.20), p<0.001) or EuroSCORE II
(3.84 (2.43–6.39) vs. 6.20 (3.58–11.10), p<0.001) in patients who received an older generation
prosthesis. However, older than third generation prosthesis remained a predictor of new-onset
AF even after forcing moderate to severe paravalvular regurgitation (p = 0.039), STS score
(p = 0.034) or EuroSCORE II (p = 0.027) into the multiple logistic regression model. Hospital
stay was longer in patients with new-onset AF (7 (4–12) days) compared to those with no AF
(4 (2–6) days), paroxysmal AF (5 (3–7) days) or non-paroxysmal AF (5 (3–7) days) (p<0.001).
The antithrombotic therapies of the patients with AF at discharge are described in Table 3.
In comparison with patients receiving any anticoagulant alone at the time of discharge, those
patients receiving no antithrombotic therapy had a greater hazard of all-cause mortality during
the follow-up, while no differences were observed relative to the other antithrombotic thera-
pies. No differences in the incidence of late stroke was observed between any of the different
antithrombotic combinations or lack thereof.
Discussion
The current study documented that AF is a common condition among patients undergoing
TAVR for severe AS with a prevalence of approximately 50%. A novel and relevant finding
was that among patients with pre-existing AF undergoing TAVR, long-term mortality was sig-
nificantly increased in those with a non-paroxysmal form of the arrhythmia, whereas
Table 1. (Continued)
Covariates No AF n = 1038 Paroxysmal AF n = 281 Non-paroxysmal AF n = 651 New-onset AF n = 160 P value
Urgent or emergency procedure 68 (6.6) 29 (10.3) 49 (7.5) 12 (7.5) 0.204
Critical preoperative state 22 (2.1) 5 (1.8) 13 (2.0) 8 (5.0) 0.109
Non-transfemoral access 100 (9.6) 36 (12.8) 100 (15.4) 51 (31.9) <0.001
Transapical access 72 (6.9) 24 (8.5) 65 (10.0) 34 (21.3) <0.001
Prosthesis type <0.001
Self-expandable 240 (23.3) 55 (19.7) 129 (19.9) 15 (9.4)
Balloon-expandable 675 (65.5) 183 (65.6) 461 (71.1) 125 (78.6)
Mechanically expanded 116 (11.3) 41 (14.7) 58 (9.0) 19 (11.9)
Newer generation prosthesis 733 (70.7) 195 (69.6) 416 (63.9) 90 (56.3) <0.001
Balloon post-dilatation 34 (3.3) 8 (2.8) 27 (4.1) 8 (5.0) 0.526
Postop. moderate or severe paravalvular regurgitation 35 (3.4) 5 (1.8) 31 (4.8) 8 (5.0) 0.111
Length of hospital stay, days 2 (4–6) 3 (5–7) 3 (5–7) 7 (4–12) <0.001
Antithrombotic therapy at discharge <0.001
None 18 (7.7) 11 (3.9) 19 (2.9) 12 (7.5)
AC 154 (14.8) 175 (62.3) 473 (72.7) 58 (36.3)
AC and SAPT 79 (7.6) 48 (17.1) 127 (19.5) 37 (23.1)
AC and DAPT 32 (3.1) 10 (3.6) 20 (3.1) 11 (6.9)
SAPT 107 (10.3) 16 (5.7) 5 (0.8) 5 (3.1)
DAPT 648 (62.4) 21 (7.5) 7 (1.1) 37 (23.1)
Continuous variables are reported as median (interquartile range); categorical variables are reported as counts and percentages.
�Data missing on 327 patients.
Abbreviations: AC, anticoagulant; AF, atrial fibrillation; CHA2DS2-VASc, congestive heart failure, hypertension, age >74 years, diabetes, history of stroke or transient
ischemic attack, vascular disease, age 65–74 years, sex category (female); DAPT, double antiplatelet therapy; eGFR, estimated glomerular filtration rate according to the
MDRD equation; MDRD, Modification of Diet in Renal Disease; NYHA, New York Heart Association; SAPT, single antiplatelet therapy; STS, Society of Thoracic
Surgery; TIA, transient ischemic attack.
https://doi.org/10.1371/journal.pone.0238953.t001
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paroxysmal AF had no effect on mortality. Secondly, new-onset AF was predicted by critical
preoperative state, transapical access technique and use of older generation TAVR prostheses
and was associated with both increased short and long-term mortality after TAVR. Incidence
of stroke during short or long-term follow-up after TAVR was unaffected by the subtype of
AF.
AF is a well-known predictor of mortality in the general population and in those with AS
[16–18]. Research has also consistently demonstrated that pre-existing AF is associated with
increased short and long-term mortality after TAVR [3, 5–10]. However, evidence has been
lacking on whether the subtype of AF affects outcomes after TAVR. To date, there has been
only one small cohort study, which reported that AF, regardless of subtype, was associated
with increased mortality at one year of follow-up [10]. Several large population-based studies
have demonstrated that in the general population paroxysmal AF confers no excess risk of
mortality after adjusting for confounding factors [19–21], which is in line with the findings of
the current work. The lack of association between paroxysmal AF and mortality most likely
pertains to an earlier stage of cardiac degeneration compared to patients with non-paroxysmal
AF.
The rate of new-onset AF in the current study was 7.2%, a finding in agreement with earlier
studies [4–6]. Somewhat conflicting evidence on the effect of new-onset AF on mortality after
TAVR has been presented in previous literature. A large meta-analysis by Sannino et al. did
not find any effect of new-onset AF on mortality [7], whereas a more recent meta-analysis by
Fig 1. Kaplan-Meier estimate of survival in patients with paroxysmal, non-paroxysmal, new-onset or no AF
undergoing transcatheter aortic valve replacement. Number at the bottom of graph are patients at risk.
https://doi.org/10.1371/journal.pone.0238953.g001
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Mojoli et al. demonstrated increased early and late mortality compared to sinus rhythm [8],
which is in agreement with the current work. A recent cohort study reported increased mortal-
ity in patients with new-onset AF even in contrast to those with previous AF [9].
Transapical access was found to be an important predictor of new-onset AF as shown also
by a previous pooled analysis [4]. The cause of excess new-onset AF associated with transapical
TAVR may be attributed to inflammatory responses associated with epicardial and pericardial
injury and ventilatory restriction, hyperadrenergic state and myocardial ischemia related to
postoperative state after minithoracotomy [4, 22, 23]. However, it is possible that the increased
Table 2. Adjusted risk estimates of study outcomes�.
No AF Paroxysmal AF Non-paroxysmal AF New-onset AF
N = 1038 N = 281 Risk estimate (95%
CI)
P value N = 651 Risk estimate (95%
CI)
P value N = 160 Risk estimate (95%
CI)
P value
Overall mortality 259
(25.0)
85
(30.2)
1.22 (0.95–1.60) 0.119 265
(40.7)
1.61 (1.35–1.92) <0.001 71
(44.4)
1.43 (1.09–1.89) 0.010
30-day mortality 19 (1.8) 10 (3.6) 1.79 (0.83–3.19) 0.136 23 (3.5) 1.73 (0.94–3.19) 0.077 10 (6.3) 2.76 (1.25–6.09) 0.012
5-year mortality 228
(22.0)
78
(27.8)
1.23 (0.94–1.60) 0.126 239
(36.7)
1.60 (1.33–1.93) <0.001 66
(41.3)
1.49 (1.12–1.99) 0.006
Early stroke 24 (2.3) 8 (2.8) 1.15 (0.51–2.61) 0.738 14 (2.2) 0.90 (0.46–1.74) 0.730 8 (5.0) 2.09 (0.92–4.76) 0.080
Late stroke 38 (3.7) 14 (5.0) 1.35 (0.72–2.54) 0.352 31 (4.8) 1.19 (0.73–1.95) 0.480 8 (5.0) 1.22 (0.55–2.69) 0.621
Early or late
stroke
60 (5.8) 20 (7.1) 1.21 (0.71–2.05) 0.489 43 (6.6) 1.08 (0.72–1.63) 0.709 16
(10.0)
1.65 (0.92–2.97) 0.094
Categorical variables are reported as counts and percentages. Risk estimates are hazard ratios for overall, 30-day and 5-year mortality and odds ratios for the other end-
points.
Abbreviations: AF, atrial fibrillation; CI, confidence interval; eGFR, estimated glomerular filtration rate; STS, Society of Thoracic Surgery; TIA, transient ischemic
attack.
�Variables considered in the adjusted analyses. Overall mortality: age, sex, third generation prosthesis, anemia, eGFR <30 mL/min/1.73m2, diabetes, pulmonary disease,
severe frailty, active malignancy, NYHA4 symptoms, coronary artery disease, acute heart failure <90 days, transapical access, left ventricle ejection fraction <50%,
extracardiac arteriopathy, combined aortic stenosis and regurgitation, length of hospital stay. 30-day mortality: third generation prosthesis, extracardiac arteriopathy,
recent myocardial infarction, acute heart failure <90 days, NYHA4 symptoms, transapical access, eGFR <30 mL/min/1.73m2, STS score, recent aortic valve balloon
valvuloplasty, length of hospital stay. 5-year mortality: age, sex, third generation prosthesis, anemia, eGFR <30 mL/min/1.73m2, diabetes, pulmonary disease, severe
frailty, active malignancy, NYHA4 symptoms, coronary artery disease, acute heart failure <90 days, transapical access, left ventricle ejection fraction <50%, extracardiac
arteriopathy, combined aortic stenosis and regurgitation, length of hospital stay. Early stroke: recent aortic valve balloon valvuloplasty. Late stroke: sex, third generation
prosthesis, anemia, eGFR <30 mL/min/1.73m2, history or stroke or TIA, previous myocardial infarction, extracardiac arteriopathy, transapical access. Early or late
stroke: sex, third generation prosthesis, anemia, eGFR <30 mL/min/1.73m2, history of stroke or TIA, previous myocardial infarction, extracardiac arteriopathy,
transapical access.
https://doi.org/10.1371/journal.pone.0238953.t002
Table 3. Antithrombotic therapy among patients with atrial fibrillation at the time of discharge from the operative center.
Antithrombotic therapy Overall mortality Late stroke
n = 1092 Adjusted HR (95% CI) P value Adjusted OR (95% CI) P value
AC 706 (64.7) Reference Reference Reference Reference
AC and SAPT 212 (19.4) 0.96 (0.75–1.22) 0.7330 0.97 (0.47–2.00) 0.942
AC and DAPT 41 (3.8) 0.78 (0.47–1.31) 0.353 0.36 (0.05–2.77) 0.328
DAPT 65 (6.0) 0.89 (0.60–1.32) 0.556 0.74 (0.21–2.57) 0.683
SAPT 26 (2.4) 0.81 (0.42–1.54) 0.513 2.40 (0.73–7.86) 0.148
None 42 (3.8) 7.15 (4.87–10.51) <0.001 0.79 (0.18–3.47) 0.759
Categorical variables are reported as counts and percentages.
Abbreviations: AC, anticoagulant; CI, confidence interval; DAPT, double antiplatelet therapy; HR, hazard ratio; OR, odds ratio; SAPT, single antiplatelet therapy.
https://doi.org/10.1371/journal.pone.0238953.t003
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rate of new-onset AF also relates to the greater burden of vascular disease in those selected for
non-transfemoral access and not the access technique itself.
A novel and interesting finding of our study was that older generation TAVR prostheses
were an independent predictor of new-onset AF. Older generations of TAVR prostheses are
associated with a distinctly higher rate of paravalvular regurgitation [24, 25]. Significant para-
valvular regurgitation, in turn, will lead to volume and pressure overload of the left heart,
which could predispose to the emergence of new-onset AF, although this association was not
observed in the current work. Additionally, newer generation prostheses induce less systemic
inflammation compared to previous generations, which could also contribute to the fewer
number of new-onset AF in this group of patients [26]. It may also be argued that the lower
risk of new-onset AF associated with the use of newer generation prostheses could be
explained by extending TAVR indication to patients at intermediate surgical risk during the
more recent years. However, the evidence from the current adjusted analysis does not support
this assumption.
AF is a major risk factor of thromboembolism and stroke, and stroke is in turn a common
severe adverse event after TAVR [7, 27]. However, no association between any subtype of AF
and stroke during the entire follow-up was observed in the current work. Indeed, more than a
third of the strokes observed in the current study occurred during the index hospitalization,
which implies a significant influence by procedural factors on early stroke incidence. Antith-
rombotic medication use is most likely an important factor behind the absence of association
of any subtype of AF and early or late stroke. It is also possible that the generally low stroke
number and the relatively short follow-up may be insufficient to draw any definitive conclu-
sions. Previous research has demonstrated somewhat different results regarding the effect of
AF on the incidence of stroke after TAVR. However, in a large meta-analysis by Sannino et al,
pre-existing AF did not affect the incidence of early or late stroke after TAVR, whereas new-
onset AF was associated with increased incidence of early, but not of late stroke [7]. Gargiuolo
et al. replicated these findings regarding new-onset AF and stroke in a more recent meta-anal-
ysis [28]. Heterogeneous use of antithrombotic medications among patients undergoing
TAVR probably contributes to the diverging outcomes between studies.
The optimal antithrombotic management after TAVR in patients with AF is unclear. Cur-
rent guidelines recommend the use of a vitamin K antagonist either alone or in combination
with an antiplatelet agent for 3 to 6 months [1, 2]. However, these recommendations are based
mainly on expert consensus, and practices vary considerably. In the current work, no differ-
ence in stroke rates was observed between the antithrombotic regimes, whereas increased mor-
tality in comparison to patients discharged with an anticoagulant medication alone was
observed only in patients, who were discharged without any antithrombotic medication. This
finding is not surprising, as these patients evidently represent a subset suffering from serious
bleeding complications or too ill to withstand the use of necessary antithrombotic medications
leading to significant predisposition for additional adverse events. The lack of association
between different antithrombotic medications in AF patients and stroke may be related to the
small number of patients discharged without an anticoagulant and the relatively short median
duration follow-up. It is also possible that those without an anticoagulant at discharge started
with one on a later date. Antiplatelet agents effectively prevent atherothrombotic strokes also
in patients with AF, which may further affect the number of strokes in these patients. Indeed,
as antithrombotic regimes were tailored according to individual risk assessment rather than a
standardized protocol, it is not possible to draw any clear conclusions on the effect of different
antithrombotic regimes on outcomes after TAVR based on the current results. Recently pub-
lished results from the POPular TAVI trial suggest that oral anticoagulation alone is advanta-
geous over oral anticoagulation in combination with clopidogrel in patients with AF
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undergoing TAVR, particularly due to fewer bleeding complications [29]. The ongoing ran-
domized ATLANTIS trial comparing anticoagulant therapy with a vitamin K antagonist to
apixaban among patients with a prior indication for oral anticoagulation therapy undergoing
TAVR will likely further illuminate this pertinent question [30].
The present findings are of clinical importance because they suggest that non-paroxysmal
AF, but not paroxysmal AF, is associated with structural changes of the atrial wall which have
prognostic importance. Fibrosis of the atrial wall is an established trigger for AF and a recent
study showed that focal left atrial fibrosis localized to the left inferior pulmonary vein antrum,
the extent of left atrial fibrosis, and enlarged left atrial volume were independently associated
with persistent atrial fibrillation rather than with paroxysmal atrial fibrillation in cardiac MRI
[31, 32]. These findings may facilitate a better clinical stratification of the extent of cardiac
damage in patients with AS [33].
There are some limitations to the current study that must be acknowledged. The main limi-
tation is the retrospective design of the study with all its inherent challenges. New-onset AF
was defined as being diagnosed during the index hospitalization for the TAVR procedure, the
duration of which was variable, which may be seen as a limitation. By extending the period of
post-operative detection, it is conceivable that the number of procedure-related new-onset AF
cases could have been increased. Additionally, no routine electrocardiographic monitoring
was performed prior to the TAVR procedure and it is therefore possible that some patients
who were classified as having new-onset AF actually had undetected paroxysmal AF. Data on
whether patients with new-onset AF had a paroxysmal or a non-paroxysmal form of the
arrhythmia was not available, which is another limitation. A notable limitation is that the
antithrombotic medication regimes between patients were not randomized and were rather
based on individual risk assessment. Moreover, antithrombotic medications were recorded at
admittance and discharge only, and possible regimen changes afterwards could not be
accounted for. Lack of bleeding data is another limitation. On the other hand, these data repre-
sent a large unselected nationwide cohort of patients undergoing TAVR with a relatively
lengthy follow-up strengthening the validity of the results. A particular strength of the study
was the accuracy and completeness of the survival data.
In conclusion, among patients undergoing TAVR, pre-existing non-paroxysmal AF and
new-onset AF are associated with increased mortality, whereas pre-existing paroxysmal AF is
not. These findings suggest that non-paroxysmal AF rather than paroxysmal AF may be associ-
ated with structural cardiac damage which is of prognostic significance. Further large-scale
studies are needed to confirm these observations.
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